الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 126 |  |  |
| | | from | 126 | | |
Abstract
The purpose of the study was to analyze the association of the ADIPOQ gene rs1501299 (+276G/T) SNPs with primary KOA susceptibility and severity, and investigate adiponectin serum level in KOA patients and its relationship with clinical, radiographic, and ultrasonographic characteristics.
The study included forty patients fulfilling the ACR criteria for KOA and forty healthy volunteers with matched age, sex and BMI. Patients were excluded from the study if they had one of the following: inflammatory arthropathies, infection or malignancy induced arthritis, previous knee injury or surgery, medications affecting the level of serum adiponectin, types 1 and 2 diabetes mellitus, chronic kidney failure, and pregnancy.
All patients were subjected to full history taking, anthropometric measurements, complete knee examination, pain assessment by VAS, and functional assessment by WOMAC scale. Plain X-ray was performed for both knees in standing antero-posterior view assessing the severity of KOA by using KL grading scale. Ultrasonography was done for all patients and the severity of KOA was assessed by using ultrasonographic grading systems.
Inflammatory markers (ESR and CRP) were assessed using BD SeditainerTM and BN Prospec system. Genotyping of ADIPOQ gene rs1501299 (+276G/T) SNPs was performed via real time polymerase chain reaction (PCR) using TaqMan single nucleotide polymorphism (SNP) genotyping assay. Plasma adiponectin level was assessed using ELISA for all participants.
The results revealed no statistically significant differences between patients and controls regarding gender, age, occupation, BMI, and WHR. Serum adiponectin level was significantly higher among patient group. On the other hand, there were no statistically significant differences between patients and controls regarding adiponectin gene expression genotypes and alleles.
There were no significant associations between ADIPOQ rs1501299 polymorphism and all findings of disease characteristics as well as adiponectin concentration.
There was no correlation between serum adiponectin and inflammatory markers (CRP and ESR). There was no relationship between serum adiponectin and VAS of pain and WOMAC scaling of pain, stiffness and difficulty performing daily activities.
There were significant negative correlations between serum adiponectin level and either BMI or WHR. The mean serum level of adiponectin was significantly lower in obese patients compared to those with overweight and normal-weight.